Eric Hodgins Takes the Helm as CTO at Precision Medicine Group
Eric Hodgins Appointed Chief Information and Technology Officer
Precision Medicine Group, a prominent player in the field of drug development and commercialization services, has recently appointed Eric Hodgins as its Chief Information and Technology Officer. Bringing over 30 years of experience in clinical and commercial technologies, Hodgins is prepared to enhance the technological framework of the company, ensuring it continues to deliver value for biopharma clients.
Focus on Innovative Technologies
In his role, Hodgins will lead the charge in developing transformative technologies essential for Precision's research and development (R&D) and commercial services. His innovative mindset and past successes will undoubtedly guide Precision in optimizing their technology capabilities as they strive to meet the ever-evolving needs of the healthcare industry.
Vision for Biopharmaceutical Solutions
Margaret Keegan, CEO of Precision, expressed great enthusiasm about Hodgins joining the team. "Eric is a visionary in the field with a deep commitment to advancing patient care and client-oriented solutions," stated Keegan. His extensive background, having previously served as Senior Vice President at IQVIA, uniquely positions him to enhance clinical trial efficiency and patient engagement while ensuring compliance with regulatory standards.
Harnessing AI and Emerging Technologies
Hodgins emphasizes the critical importance of technology in both clinical development and commercialization. He noted that developments in AI and other emerging technologies have been pivotal in providing real-time insights necessary for biopharma companies. This capacity allows these organizations to meet their patients' needs more effectively.
Professional Background of Eric Hodgins
Before his tenure at Precision, Hodgins founded a clinical technology startup, which he successfully sold to a leading clinical research organization (CRO). He then spent years building the technological ecosystem of this global CRO and successfully ran businesses focused on patient engagement and ensuring safety, regulatory, and quality standards. Hodgins holds a BS in Mechanical Engineering from the University of Texas, Austin, underscoring his technical expertise.
About Precision Medicine Group
Founded in 2012, Precision Medicine Group (PMG) specializes in next-generation approaches to drug development and commercialization. The firm supports life sciences innovators in moving their discoveries from molecule to market through a comprehensive suite of integrated services, including biomarker intelligence and global market access consulting. With over 3,500 employees, PMG has established a robust presence in North America, Europe, and Asia, further solidifying its role as an industry leader.
Frequently Asked Questions
Who is Eric Hodgins?
Eric Hodgins is an industry veteran with over 30 years of experience in clinical and commercial technologies, recently appointed as Chief Information and Technology Officer at Precision Medicine Group.
What will Hodgins focus on at Precision Medicine Group?
He will focus on developing transformative technologies for Precision's R&D and commercial services, enhancing their technological capabilities.
What was Hodgins' previous role before joining Precision?
He served as a Senior Vice President at IQVIA, where he worked on improving clinical trial efficiency and patient engagement technologies.
Why is technology important in biopharmaceuticals?
Technology plays a crucial role in clinical development and commercialization by providing real-time insights that help biopharma companies better meet patient needs and improve outcomes.
What services does Precision Medicine Group provide?
PMG offers integrated services including biomarker intelligence, lab services, and global consulting to help innovators in drug development move their discoveries to market.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
